We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Oculis establishes its US headquarters in Boston, MA, a world-renowned biotech hub, to support its continued expansion following OCS listing into NASDAQ Oculis’s finance and development team...
ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.If approved, OCS-01 has the potential to become the first once-daily, topical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.002 | 2.43902439024 | 0.082 | 0.088 | 0.08 | 183273 | 0.08212969 | DE |
4 | 0.012 | 16.6666666667 | 0.072 | 0.125 | 0.07 | 450596 | 0.0959015 | DE |
12 | 0.019 | 29.2307692308 | 0.065 | 0.125 | 0.061 | 303335 | 0.08495635 | DE |
26 | -0.006 | -6.66666666667 | 0.09 | 0.125 | 0.061 | 181552 | 0.08616991 | DE |
52 | -0.076 | -47.5 | 0.16 | 0.28 | 0.061 | 201362 | 0.11067474 | DE |
156 | -0.376 | -81.7391304348 | 0.46 | 0.67 | 0.061 | 272668 | 0.31755955 | DE |
260 | -0.046 | -35.3846153846 | 0.13 | 0.67 | 0.061 | 419799 | 0.23423635 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions